{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:43Z","timestamp":1791618943896,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>The purpose of this study was to comprehensively evaluate the long\u2010term adverse effects of proton pump inhibitors (PPIs) compared with histamine\u20102 receptor antagonists (H2RAs) in kidney transplant recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort compared 582 patients treated with PPI with 705 patients treated with H2RA and evaluated adverse effects throughout their course of acid suppressant therapy to a maximum of nine years posttransplant. The primary outcome of interest was renal function at 1 year posttransplant; secondary outcomes included renal function at 30\u00a0days, 3, 5, and 9\u00a0years posttransplant as well as rejection, electrolyte and laboratory abnormalities, osteoporosis, pneumonia, and <jats:italic>Clostridium difficile<\/jats:italic> infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Renal function did not significantly differ at any timepoint posttransplant. Rejection rates and <jats:italic>Clostridium difficile<\/jats:italic> infections were similar between groups; osteoporosis and pneumonia rates were numerically higher in the PPI treated arm but did not reach statistical significance. Proton pump inhibitor (PPI) treated patients were more likely to experience hypomagnesemia requiring supplementation. High dose PPI treated patients had significantly higher rates of pneumonia and osteoporosis compared with H2RA treated patients. Patients were maintained on PPI therapy for an average of 5 years and H2RA therapy for 3 years posttransplant, the majority without a clear indication for therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was no difference in renal function, rejection, or graft loss between PPI and H2RA treated patients. The majority of patients were maintained on PPI therapy for several years posttransplant without a clear indication; critical evaluation of ongoing need for acid suppressant therapy in the posttransplant course should be an area of future focus.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2470","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T23:47:07Z","timestamp":1602287227000},"page":"1082-1088","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Choice of Acid Suppressant Therapy and Long\u2010Term Graft Outcomes After Kidney Transplantation"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-5581","authenticated-orcid":false,"given":"Spenser E.","family":"January","sequence":"first","affiliation":[{"name":"Department of Pharmacy Barnes\u2010Jewish Hospital Saint Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Progar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Barnes\u2010Jewish Hospital Saint Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Nesselhauf","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Barnes\u2010Jewish Hospital Saint Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Hagopian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Barnes\u2010Jewish Hospital Saint Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Malone","sequence":"additional","affiliation":[{"name":"Division of Nephrology Washington University Physicians Saint Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2004.tb00394.x"},{"issue":"7","key":"e_1_2_6_3_1","first-page":"1508","article-title":"Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus","volume":"30","author":"Riskalla MM","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307073090105"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03407.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.74"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0325-4"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw470"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7193"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39335-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/09537104.2014.880108","article-title":"Pantoprazole\u2010induced thrombocytopenia in patients with upper gastrointestinal bleeding","volume":"1","author":"Binneto\u011flu E","year":"2015","journal-title":"Platelets"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9170-1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2037"},{"issue":"2","key":"e_1_2_6_14_1","first-page":"86","article-title":"Proton pump inhibitors do not increase the risk of acute rejection","volume":"72","author":"Boekel GAJ","year":"2014","journal-title":"Neth J Med"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000436100.65983.10"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v9.i2.35"},{"issue":"6","key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfaa111","article-title":"Effect of proton\u2010pump inhibitor pantoprazole on mycophenolic acid exposure in kidney and liver transplant recipients (IMPACT study): a randomized trial","volume":"35","author":"Sunderland A","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011412968"},{"issue":"3","key":"e_1_2_6_19_1","article-title":"Proton\u2010pump inhibitor utilization is associated with higher rates of Clostridium difficile infection and hypomagnesemia after kidney transplant","volume":"17","author":"Kipp G","year":"2017","journal-title":"Am J Transplant"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122162"},{"key":"e_1_2_6_21_1","first-page":"300","article-title":"Use of proton\u2010pump inhibitors is associated with lower magnesium and iron status and excess mortality in renal transplant recipients","volume":"18","author":"Gomes\u2010Neto A","year":"2018","journal-title":"Am J Transplant"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091382"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010258"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1526924816669725"},{"key":"e_1_2_6_25_1","article-title":"Proton pump inhibitors, but not H2 receptor antagonists, are associated with incident fractures among kidney transplant recipients","author":"Lyu B","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"e_1_2_6_26_1","article-title":"Effects of proton pump inhibitors on kidney transplant recipients","volume":"32","author":"Uludag O","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001035"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204231"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1243"},{"issue":"16","key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community\u2010acquired pneumonia and use of gastric acid\u2010suppressive drugs","volume":"292","author":"Leheij R","year":"2004","journal-title":"JAMA"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060068"},{"issue":"8","key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2165\/00003495-200161080-00013","article-title":"Valganciclovir","volume":"61","author":"Curran M","year":"2001","journal-title":"Drugs"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2006.02.077"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:22:36Z","timestamp":1761038556000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/phar.2470"],"URL":"https:\/\/doi.org\/10.1002\/phar.2470","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}